![]() |
|
|
Vol. 294, Issue 1, 356-362, July 2000
2-Adrenoceptor Subtype,
Which Functions as
2-Autoreceptor in Human
Neocortex1
Sektion Klinische Neuropharmakologie der Neurologischen Universitätsklinik, Freiburg, Germany
| |
Abstract |
|---|
|
|
|---|
The pharmacological properties of the
2-adrenergic
receptors regulating the release of norepinephrine were investigated in human neocortex. Slices were preincubated with
[3H]norepinephrine, superfused under blockade of
transmitter reuptake, and stimulated electrically. First, the
autoinhibitory circuit of [3H]norepinephrine release was
analyzed quantitatively by estimation of the
Kd of norepinephrine at the
2-autoreceptor (10
7.99 M), the
concentration of the endogenous transmitter causing this autoinhibition
at a stimulation frequency of 3 Hz (10
7.61 M), and the
maximum inhibition obtainable through the autoreceptor (83%). Second,
antagonist pKb values of nine antagonists
were determined by using their pEC50 values (negative
logarithms of antagonist concentrations that increased the electrically
evoked overflow of tritium by 50%) against the release-inhibiting
effect of the endogenous transmitter. When compared with binding or
functional data from the literature, the pKb
values correlated best with the antagonist affinities at
2A binding sites. In contrast, the correlations with
2B,
2C, and
2D sites were
not as good. It is concluded that in human neocortex prejunctional
autoreceptors are
2A.
| |
Introduction |
|---|
|
|
|---|
In
1992, Raiteri and colleagues concluded that the presynaptic
2-autoreceptors that modulate norepinephrine
release in the human neocortex are distinct from
2B and
2C and are
either
2A or
2D. This
conclusion was mainly based on three findings: the potent
release-inhibiting effect of oxymetazoline; the potent antagonism by
yohimbine as opposed to the weak antagonism by prazosin and
2-{2-[4-(o-methoxyphenyl)piperazin-1-yl]ethyl}-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione (ARC 239) of the release-inhibiting effect of clonidine; and the marked
release-enhancing effect of yohimbine as opposed to the lack of a
release-enhancing effect of prazosin and ARC 239 when these antagonists
were given alone. All observations were in accord with the affinities
of oxymetazoline, yohimbine, prazosin, and ARC 239 for
2A- and
2D-adrenoceptors but were not compatible with
their affinities for
2B- and
2C-adrenoceptors (Raiteri et al., 1992
).
It is now thought that the
2A- and
2D-adrenoceptors are species orthologs, of
which only one occurs in a given species, and that humans possess the
2A version, whereas rodents possess the
2D version (see Bylund, 1995
). Human
neocortical
2-autoreceptors therefore should
be
2A. If so, they would obey the rule that the main mammalian
2-autoreceptors belong to
the
2A/D branch of the adrenoceptor tree
(Trendelenburg et al., 1993
, 1999
; see Docherty, 1998
). Recent evidence
indicates, however, that noradrenergic neurons in addition may possess
2C-autoreceptors (Trendelenburg et al., 1997
;
see Docherty, 1998
; Ho et al., 1998
; Altman et al., 1999
).
Because the identification of a receptor type by means of an agonist
(oxymetazoline in the work of Raiteri et al., 1992
) is ambiguous and
because these authors used only three antagonists, we reinvestigated
the subtype to which the
2-autoreceptors
belong in the human neocortex. For this purpose, we quantified the
release-enhancing effect of nine antagonists, including prazosin and
ARC 239. The concentration-response data were evaluated by fitting a
logistic function, which yielded the maximal enhancement and the
EC50 of the antagonist. The effect of exogenous
norepinephrine under autoinhibition-free as well as autoinhibition
conditions was also studied. The evaluation of the norepinephrine
concentration-response curves suggested proportionality between
2-autoreceptor occupation and response and
allowed the conversion of the EC50 values of the
antagonists into their dissociation constants,
Kb values, at the autoreceptors. Thus,
the subclassification of the
2-autoreceptor in
human neocortex was possible, based on functionally defined
Kb values of antagonists in comparison
with corresponding values from the literature. The conversion of
EC50 to Kb
justified the use of the functional parameter Kb as an estimate of the antagonist
dissociation constant. Thus, the bias or shift between
EC50 values and dissociation constants of binding
experiments could be bridged.
| |
Materials and Methods |
|---|
|
|
|---|
Fresh neocortical tissue was obtained from patients during surgical access to subcortical tumors. The procedure was approved by the local Ethics Committee. The patients (n = 42) were of either sex and were between 21 and 86 years old. After premedication with midazolam or chlordiazepoxide, patients were anesthetized with thiopental, fentanyl, or flunitrazepam. Pancuronium was given for muscle relaxation. The tissue was immersed in ice-cold medium (see below) and processed immediately.
Cortical slices, 350 µm thick and perpendicular to the surface, were
incubated with 0.1 µM (
)-[3H]norepinephrine
in 4 ml of medium for 45 min at 37°C and then superfused with
[3H]norepinephrine-free medium at 0.4 ml/min.
For electrical stimulation, rectangular pulses of 2-ms width and a
voltage drop of 11 V across the electrodes of each superfusion chamber
were used, yielding a current strength of approximately 76 mA
(Stimulator I; Hugo Sachs Elektronik, Hugstetten, Germany). Four
stimulation periods were applied (S1 to
S4); they began after t = 75, 110, 145, and 180 min (t = 0 being the start of
superfusion). To evoke release free of autoinhibition, each stimulation
period consisted of two trains of 4 pulses/100 Hz, with a train
interval of 2 min [pseudo-one-pulse conditions; Singer, 1988
; Allgaier
et al., 1995
]. To evoke autoinhibited release, each stimulation period
consisted of 90 pulses/3 Hz. Successive 5-min samples of the
superfusate were collected from t = 60 min onward.
Unlabeled norepinephrine (tested under pseudo-one-pulse conditions as well as at 90 pulses/3 Hz) or
-adrenoceptor
antagonists (tested at 90 pulses/3 Hz only) were added at increasing
concentrations 15 min before S2,
S3, and S4. At the end of
experiments, tissues were dissolved, and tritium was determined in
superfusate samples and tissues.
The medium used for tissue collection, incubation, and superfusion contained 118 mM NaCl, 1.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4, 25 mM NaHCO3, 1.2 mM KH2PO4, 11 mM glucose, and 0.57 mM ascorbic acid. It was saturated with a mixture of 95% O2 and 5% CO2. The superfusion medium also contained 1 µM desipramine or, in experiments with >1 µM exogenous norepinephrine, 10 µM desipramine plus 10 µM (+)-oxaprotiline.
The outflow of tritium was calculated as a fraction of the tritium
content of the slice at the onset of the respective collection period
(fractional rate; min
1). The overflow elicited
by electrical stimulation was calculated as the difference: total
tritium outflow during the collection period in which stimulation was
applied and during the two collection periods thereafter minus
estimated basal outflow; basal outflow was assumed to decline linearly
from the collection period before to the collection period 10 to 15 min
after onset of stimulation. The evoked overflow was then expressed as a
percentage of the tritium content of the slice at the time of
stimulation. For further evaluation, ratios were calculated for the
overflow evoked by S2, S3,
and S4 and the overflow evoked by
S1. Moreover, effects of exogenous norepinephrine
and of the antagonists were calculated for each single slice as a
percentage of control, using the corresponding mean average control
S2/S1,
S3/S1, and
S4/S1 ratios
(solvent-treated slices, no agonist, no antagonist) as the reference.
Drug effects on the basal efflux of tritium were evaluated similarly,
based on values immediately before stimulation periods
(b1, etc.).
Concentration-response data were evaluated as follows. In the case of
the inhibitory effect of exogenous norepinephrine under autoinhibition-free conditions, a logistic function was fitted to the
"percentage of control" data to yield the maximal effect of
norepinephrine Imax observed, its
IC50, and the slope parameter c (eq. 7 of Feuerstein and Limberger, 1999
). In the case of the effect of
exogenous norepinephrine under autoinhibition conditions, a special
function was fitted to the data that describes the combined effects of
exogenous and endogenous norepinephrine, assumes the proportionality of
receptor occupation and the effect of norepinephrine, and yields the
maximal obtainable effect of norepinephrine under autoinhibition-free
conditions Imax derived, the
dissociation constant Kd of the
norepinephrine-autoreceptor complex, and the concentration of released
transmitter norepinephrine at the autoreceptors in the absence of
exogenous norepinephrine [NEtr] (biophase
concentration; eq. 14 of Feuerstein and Limberger, 1999
). In the case
of the facilitatory effect of the antagonists, we fitted a logistic
function to the percentage of control data to obtain the
Emax of the antagonist and its
EC50 [eq. 7 of Feuerstein and Limberger, 1999
,
adapted for enhancement instead of inhibition, i.e.,
Sx/S1 = 1 + Emax × 10
p[B]/(10
pEC50 + 10
p[B]), where p[B] is the negative
logarithm of the applied antagonist concentration and
pEC50 is the negative logarithm of
EC50]. The conversion of antagonist
EC50 to antagonist dissociation constant Kb was then based on the
Kd and Imax
derived of norepinephrine, determined independently as
described above.
Results are given as arithmetic means or estimates with 95% confidence
intervals (CI95) in parentheses to
indicate statistical probability (Altman, 1991
). n is the
number of brain slices.
Purchased drugs were
(
)-[ring-2,5,6-3H]norepinephrine, specific
activity 40.5 Ci/mmol (DuPont, Dreieich, Germany); (
)-norepinephrine hydrogen tartrate, desipramine HCl, corynanthine HCl, (±)-idazoxan HCl
(Sigma, Deisenhofen, Germany); (+)-oxaprotiline HCl, phentolamine HCl
(Novartis, Basel, Switzerland); spiroxatrine,
(±)-2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane HCl
(WB4101) (Biotrend, Köln, Germany); rauwolscine HCl (Roth, Karlsruhe, Germany); prazosin HCl (Pfizer, Karlsruhe);
6-chloro-9-((3-methyl-2-butenyl)oxy)-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepine maleate (SKF104078) (Smith Kline Beecham, Palo Alto, CA); and ARC 239 (Thomae, Biberach, Germany). Drugs were dissolved in distilled water,
except for WB4101 (1 mM HCl) and spiroxatrine (10 mM HCl).
| |
Results |
|---|
|
|
|---|
The basal outflow of tritium (b1) from
slices superfused with medium containing 1 µM desipramine was 0.0034 (0.0033, 0.0035) min
1 (n = 389), the overflow of tritium elicited by two trains of 4 pulses/100
Hz (S1) averaged 0.69 (0.64, 0.74) % of tissue
tritium (n = 132), and the overflow elicited by 90 pulses/3 Hz (S1) was 3.07 (2.92, 3.23) % of
tissue tritium (n = 257). When the medium contained 10 µM desipramine and 10 µM (+)-oxaprotiline, the basal outflow of
tritium as well as the evoked overflow were similar; 10 µM
desipramine and 10 µM (+)-oxaprotiline were used in experiments with
high concentrations of unlabeled norepinephrine (>1 µM) to ensure
blockade of the uptake of the unlabeled amine.
Stimulation by two trains of 4 pulses/100 Hz led to autoinhibition-free
release of [3H]norepinephrine, as shown
previously (Allgaier et al., 1995
) and confirmed here by the lack of an
overflow-enhancing effect of 1 µM rauwolscine, added after
S1 (n = 9 versus 6 controls). Stimulation by 90 pulses/3 Hz, in contrast, led to autoinhibited release, as shown by the effects of the antagonists (see below).
Effect of Exogenous Norepinephrine.
Unlabeled norepinephrine,
when added before S2, S3,
and S4 at increasing concentrations,
progressively reduced the electrically evoked overflow of tritium, both
under autoinhibition-free conditions (Fig.
1A) and under conditions in which
autoinhibition developed (Fig. 1B). Norepinephrine did not change the
basal efflux of tritium. The concentration-response curve in Fig. 1A
was obtained by logistic curve fitting (eq. 7, Feuerstein and
Limberger, 1999
). The curve in Fig. 1B was obtained by fitting a
function that takes the effect of transmitter norepinephrine into
consideration and is based on the assumption of proportionality between
receptor occupation by norepinephrine and effect (eq. 14, Feuerstein
and Limberger, 1999
). The two concentration-response curves obviously
differ: under autoinhibition conditions (Fig. 1B), the curve is shifted to the right and the maximal observed degree of inhibition is smaller.
The parameters estimated from the curves are shown in Table
1. The parameters obtained under
autoinhibition-free conditions by logistic curve fitting can be read
easily from Fig. 1A: Imax observed is
the asymptotic maximal inhibition, which the experimental curve approaches at high concentrations of exogenous norepinephrine, and
pIC50 is the abscissa of the point of inflection
(Fig. 1A). The parameters derived from the data obtained under
autoinhibition conditions, in contrast, cannot be read immediately from
inspection of Fig. 1B: Imax derived is
not the asymptotic maximal inhibition that the experimental curve
approaches at high concentrations of exogenous norepinephrine and is
superimposed on a background of ongoing autoinhibition, but it is the
maximal inhibition obtainable with norepinephrine, whether released or
exogenous, against an autoinhibition-free background. Moreover,
Kd is not the concentration of
norepinephrine causing 50% of the asymptotic maximal inhibition of the
experimental curve but is the dissociation constant of the
norepinephrine-autoreceptor complex, calculated on the basis of
proportionality between receptor occupation and effect, as mentioned.
|
|
Effect of
-Adrenoceptor Antagonists.
As shown in Fig.
2, all antagonists, when added before
S2, S3, and
S4 at increasing concentrations, increased the
overflow of tritium evoked by 90 pulses/3 Hz, indicating autoinhibition of transmitter release. For each antagonist, the data were evaluated by
logistic curve fitting
[E/Emax = 10L/(10
pEC50 + 10L), where L is the used log
concentrations (M) of the antagonists]. The individual
E = Sx/S1
values scattered considerably, and clear maxima were not reached for
several antagonists (Fig. 2). For these reasons, probably, the
iterative calculations used to estimate the confidence intervals of the
logistic parameters Emax and
pEC50 and an additional slope factor c
did not converge when all three were left unconstrained. The slope
factor, c, therefore, was constrained to 1 (see function
E/Emax above). The
parameter estimates are summarized in Table
2.
|
|
Kb can be comprehended by considering
the diagram in Fig. 3, which uses the
graph of Fig. 1A.
|
| |
Discussion |
|---|
|
|
|---|
The subclassification of
2-autoreceptors
in human neocortex was achieved by using calculated dissociation
constants, Kb values, of
antagonist-autoreceptor complexes of nine
-adrenoceptor antagonists in comparison to binding or functional data on these antagonists from
the literature. The antagonist Kb
values were obtained from their concentrations causing half-maximal
disinhibition, EC50 values. The following
consideration was the rationale of this conversion,
EC50
Kb.
Usually the evaluation of the disinhibition of release to assess the
affinity of release-enhancing antagonists is limited to the calculation
of antagonist EC50 values that are not
Kb values (e.g., Limberger et al.,
1995a
,b
). This restriction can be surmounted by the knowledge of the
relationship between EC50 and
Kb. We first analyzed the interplay of
exogenous and endogenous norepinephrine at the autoreceptors, using a
previously developed model. The model assumes proportionality between
receptor occupation and effect of norepinephrine or, in other words,
assumes that the Kd of norepinephrine
equals its concentration causing half-maximal inhibition,
IC50, of
[3H]norepinephrine release under
autoinhibition-free conditions. It should be noted that the
IC50 of exogenous norepinephrine under autoinhibition-free conditions, 10
8.07 M, in
fact was almost identical to the calculated
Kd, 10
7.99 M
(Table 1). Thus, the present experiments have for the first time
established the Kd of norepinephrine
at a central human
2-autoreceptor in
functional experiments. The above-mentioned assumption of
proportionality as a prerequisite for IC50 = Kd is supported by the estimate near unity of the slope factor, c (0.98, Table 1). Because of the limited number of data points of Fig. 1A and the small
S1 values (0.69% of tissue tritium) that
increased the variation in the S2/S1 ratio, the
CI95 of c, however, was large (0.65, 1.75). This precludes a low error probability of the statement
c = 1 (see Agneter et al., 1997
; Feuerstein and
Limberger, 1999
). Accordingly, the statement IC50 = Kd would also have a rather large
error probability if it was only based on this large
CI95 of c. We tried, therefore, to
increase the specificity of the estimate of c by reassessing this value from the data of Fig. 1B. In other words, the "logistic components" of eq. 14 of Feuerstein and Limberger (1999)
were endowed
with a slope factor c, and this amended function was then refitted to the data of Fig. 2B with fixed values for
pKd = 7.99 and Imax
derived = 0.83 (Table 1), i.e., with a reduction of the number of parameters to reach convergence. This seemed reasonable because the maximum
2-autoreceptor-mediated
effect had to be the same in the presence and in the absence of
autoinhibition and because the pKd
(
pIC50 of Fig. 1B) was nearly identical to the
pIC50 of Fig. 1A. The refit yielded a value for
p[NEtr] corresponding to that of Table 1 (not
shown) and an additional c of 1.03 (0.64, 1.42). Now two
similar estimates for c were available, and their mean with
deviation could be calculated (using the approximate standard errors of
c, 0.17 and 0.18): 1.01 (0.77, 1.24). Thus the
CI95 of this mean c became
considerably smaller, which improved our evidence for assuming
c = 1 or IC50 = Kd.
The dissociation constants Kb of the
antagonists were calculated by the use of their
EC50 values, the
Kd (=IC50) of
norepinephrine, Imax observed obtained
under autoinhibition-free conditions, and the calculated endogenous
concentration [NEtr]. In addition, the observed
mean of the maximum disinhibition by the antagonists, 60% (Table 2),
was considered as follows. A theoretical maximum disinhibition,
Sxmax/S1, can be calculated
on the basis of the values of Table 2. Sxmax is
the stimulation-induced transmitter release that is not inhibited by
the endogenous agonist [NEtr], or, in other
words, Sxmax is the stimulation-induced
transmitter release when the autoreceptor is completely blocked (when
the concentration of the antagonist [B]
). At
S1, however, the stimulation-induced transmitter
release is diminished to S1 = 1
Imax observed × 10
pNEtr/(10
pKd + 10
pNEtr) [compare eq. 9 of Feuerstein and
Limberger (1999)
]. Thus
Sxmax/S1 = 1/(1
0.79 × 10
7.61/(10
8.07 + 10
7.61)) = 2.39. The theoretically
expected value of 2.39, or an increase by 139%, is at variance with
the observed mean of maximum disinhibition, which was 1.60, or an
increase by 60% at the highest antagonist concentrations used (1-10
µM). This discrepancy may be due to the following condition. At the
highest antagonist concentrations (up to 1000-fold of the
Kb values) additional, nonspecific
effects of the antagonists, not related to the
2-autoreceptor under investigation, must be
taken into account. These nonspecific effects are probably inhibitory,
not stimulatory, in nature, i.e., they may diminish the increase in the
evoked [3H]norepinephrine release because
action potential-evoked, exocytotic release is a highly specific
phenomenon that is dependent on the integrity of the neuronal
environment. Decreasing nonspecific effects are much more likely than
increasing nonspecific effects. As one example of perturbations by high
antagonist concentrations of the release process local anesthetic
inhibitory effects of yohimbine and rauwolscine at higher
concentrations are well known (e.g., Goodall et al., 1984
). Therefore,
depressant, not stimulatory, effects of the antagonists at
concentrations that are much higher than their
Kb values may be assumed, and the
evaluation of their concentration-disinhibition curves may be amended
as follows. The depressions of the concentration-disinhibition curves
of the antagonists at their highest concentrations, but not at rather low concentrations specific for
-adrenoceptors, correspond to the
condition of an uncompetitive, use-dependent antagonism, as opposed to
a noncompetitive antagonism (Segel, 1975
; Jackisch et al., 1994
). If
fitted with the usual logistic function, e.g., eq. 5 of Feuerstein and
Limberger (1999)
, an apparent EC50 is obtained
that is too low. To obtain a real EC50,
E/Emax = 10L/(10
pEC50 + 10L × Depr-Emax) should be used, where
Depr-Emax is the relative extent to
which the uncompetitive mechanism depresses
Emax, instead of
E/Emax = 10L/(10
pEC50 + 10L). In our case,
Depr-Emax is 2.39/1.60 = 1.49. With respect to the quantitatively dissimilar depressions by the nine
antagonists, note that most of the CI95 values of
the Emax values of Table 2 overlap,
suggesting a roughly similar depression of the theoretical maximum
disinhibition. Therefore, 1.49 may be roughly the factor by which the
too low EC50 obtained with
E/Emax = 10L/(10
pEC50 + 10L) may be corrected to get a more realistic
EC50, according to E/Emax = 10L/(10
pEC50 + 10L × Depr-Emax) (Jackisch et al., 1994
).
This correction yields the pEC50-corr values of
Table 2.
When the values pIC50,
p[NEtr], Imax
observed, EC50-corr are introduced
into eq. 7 of Feuerstein and Limberger (1999)
, step 5 in Fig. 3, (1 + [EC50-corr]/Kb) = 8.37 or pKb = pEC50-corr + 0.87 is obtained. The corresponding
Kb values for the antagonists represent the first dissociation constants of antagonists at human cerebral autoreceptors obtained in functional experiments (Table 2).
To subclassify the
2-autoreceptors, the
autoreceptor pKb values were compared
with dissociation constants at known subtypes by means of a correlation
analysis (Table 3), as has become usual in the literature, e.g., Bylund et al. (1992)
. Note that use of the
pEC50 values in the correlation analyses would
have sufficed for the identification of the
2-autoreceptor subtype because the subsequent
transformation to pKb values has no
effect on the correlation coefficients. However, apart from obtaining
accurate pKb values, we wanted to
demonstrate that the potency of an antagonist in disrupting the
autoinhibitory circuit of transmitter release is a direct measure of
its dissociation constant at the receptor to be blocked.
|
The known subtypes of the literature were, first, prototypical native
2 radioligand binding sites (Table 3A);
second, radioligand binding sites in COS cells transfected with
2-adrenoceptor genes (Table 3B); and third,
previously subclassified
2-autoreceptors (Table 3C). Table 3 shows that the dissociation constants of the
antagonists at the human neocortical autoreceptors correlate significantly and without exception with their dissociation constants at both
2A and
2D
binding sites or receptors; correlations with
2B and
2C binding
sites or receptors are not significant (exception: the
2C binding sites in opossum kidney cells;
Table 3A). Moreover, Table 3 shows that the coefficients for the
correlation with
2A are generally higher than
for the correlation with
2D, the error
probability is generally lower in the former than in the latter case,
and the slopes of the regression lines for
2A
are generally closer to unity. We conclude that the
2-autoreceptors in human brain cortex are
2A.
Presynaptic
2-autoreceptors have also been
subclassified in the human saphenous vein, kidney, and heart. In the
saphenous vein, the receptors were suggested to be
2A (Molderings and Göthert, 1995
),
whereas in the kidney and heart they were initially classified as
2C (Trendelenburg et al., 1994
; Rump et al.,
1995
). A reinvestigation of the kidney receptors, however, also yielded
an
2A diagnosis (Trendelenburg et al., 1997
).
Overall,
2A (i.e., genetically
2A/D) autoreceptors seem to predominate in
humans, as they do in various animal species (see the Introduction).
In summary, this paper shows that it is possible to analyze
quantitatively the autoinhibitory circuit of
[3H]norepinephrine release in human neocortex
tissue, i.e., to estimate the biophase concentration of the transmitter
in relation to its Kd, and to
calculate true, unbiased dissociation constants of antagonists by
evaluation of their disinhibition of
[3H]norepinephrine release. The functionally
obtained pKb values at the presynaptic
2-autoreceptors in human brain cortex
correlated highly with pKb values at
previously subclassified
2A sites, but did not
correlate significantly or correlated much less well with
pKb values at
2B,
2C, and
2D sites. It is concluded that the
2-autoreceptors in human neocortex are
2A.
| |
Acknowledgment |
|---|
We are very grateful to Prof. Dr. K. Starke for critical and constructive comments.
| |
Footnotes |
|---|
Accepted for publication April 4, 2000.
Received for publication November 30, 1999.
1 This work was supported by the Deutsche Forschungsgemeinschaft (SFB 505, TP C4, C8).
2 Present address: Neurochirurgische Universitätsklinik, Breisacherstrasse 64, D-79106 Freiburg, Germany.
3 Present address: Pharmakologisches Institut der Universität Freiburg, Hermann-Herder-Strasse 5, D-79104 Freiburg, Germany.
Send reprint requests to: Dr. T. J. Feuerstein, Sektion Klinische Neuropharmakologie der Neurologischen Universitätsklinik, Breisacherstrasse 64, D-79106 Freiburg, Germany. E-mail: feuer{at}ukl.uni-freiburg.de
| |
Abbreviations |
|---|
ARC 239, 2-{2-[4-(o-methoxyphenyl)piperazin-1-yl]ethyl}-4,4-dimethyl-1,3(2H,4H)-isoquinolinedione; WB4101, (±)-2-(2,6-dimethoxyphenoxyethyl)aminomethyl-1,4-benzodioxane HCl; SKF104078, 6-chloro-9-((3-methyl-2-butenyl)oxy)-3-methyl-1H-2,3,4,5-tetrahydro-3-benzazepine maleate; CI95, 95% confidence interval.
| |
References |
|---|
|
|
|---|
2A-adrenergic receptor knockout mice.
Mol Pharmacol
56:
154-161
2C adrenergic receptor subtype in the opossum kidney and in the OK cell line.
J Pharmacol Exp Ther
259:
323-329
2 adrenergic receptor subtypes.
Ann NY Acad Sci
763:
1-7[Medline].
2-adrenergic receptors: Comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.
Mol Pharmacol
42:
1-5[Abstract].
1- and
2-adrenoceptors.
Eur J Pharmacol
361:
1-15[Medline].
-conotoxin GVIA.
J Pharmacol Exp Ther
252:
778-785
2-adrenoceptors on serotonergic nerve endings in human and rat neocortex.
J Neurochem
61:
474-480[Medline].
2-adrenoceptor mediating prejunctional inhibition in rat atrium and cerebral cortex.
Naunyn-Schmiedeberg's Arch Pharmacol
357:
634-639[Medline].
2-adrenoceptors:
2A-Autoreceptors in rabbit atria and kidney.
Naunyn-Schmiedeberg's Arch Pharmacol
352:
31-42[Medline].
2-adrenoceptors:
2D-Autoreceptors in mouse brain.
Naunyn-Schmiedeberg's Arch Pharmacol
352:
43-48[Medline].
2-autoreceptors in the rabbit pulmonary artery and human saphenous vein.
Naunyn-Schmiedeberg's Arch Pharmacol
352:
483-490[Medline].
2A adrenergic receptor: The pharmacological properties of the bovine and rat receptors differ from the human and porcine receptors.
J Pharmacol Exp Ther
271:
735-740
2-autoreceptors in human brain cortex.
Br J Pharmacol
107:
1146-1151[Medline].
2C-Adrenoceptor-modulated release of noradrenaline in human right atrium.
Br J Pharmacol
116:
2617-2624[Medline].
2D-adrenergic receptors in bovine pineal gland.
Mol Pharmacol
40:
235-241[Abstract].
2-autoreceptors in
2A/D-adrenoceptor-deficient mice.
Naunyn-Schmiedeberg's Arch Pharmacol
360:
540-551[Medline].
2-Adrenergic receptors of the
2C subtype mediate inhibition of norepinephrine release in human kidney cortex.
Mol Pharmacol
45:
1168-1176[Abstract].
2-autoreceptors in brain cortex:
2D in the rat and
2A in the rabbit.
Naunyn-Schmiedeberg's Arch Pharmacol
348:
35-45[Medline].
2-autoreceptors: Rat vena cava, rat atria, human kidney and guinea-pig urethra.
Naunyn-Schmiedeberg's Arch Pharmacol
356:
721-737[Medline].
This article has been cited by other articles:
![]() |
M. Raiteri Functional pharmacology in human brain. Pharmacol. Rev., June 1, 2006; 58(2): 162 - 193. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||